Expert opinion on therapeutic patents

Keyphrases

Publications

volume 34, number 4, 2024

Esther C Y Lee, Kyle D Reichl, Ariamala Gopalsamy
Synthetic lethality: targeting the SMARCA2 bromodomain for degradation in SMARCA4-deficient tumors - a review of patent literature from 2019-June 2023. Expert opinion on therapeutic patents 34 (4) (2024)
Jamshed Iqbal, Sehrish Bano, Imtiaz Ali Khan, Qing Huang
A patent review of P2X7 receptor antagonists to treat inflammatory diseases (2018-present). Expert opinion on therapeutic patents 34 (4) (2024)
Petar Iliev, Carolin Jaworski, Carmen Wängler, Björn Wängler, Brent D G Page, Ralf Schirrmacher, Justin J Bailey
Type II & III inhibitors of tropomyosin receptor kinase (Trk): a 2020-2022 patent update. Expert opinion on therapeutic patents 34 (4) (2024)
Jamshed Iqbal, Sehrish Bano, Imtiaz Ali Khan, Qing Huang
A patent review of P2X7 receptor antagonists to treat inflammatory diseases (2018-present). Expert opinion on therapeutic patents 34 (4) (2024)
Petar Iliev, Carolin Jaworski, Carmen Wängler, Björn Wängler, Brent D G Page, Ralf Schirrmacher, Justin J Bailey
Type II & III inhibitors of tropomyosin receptor kinase (Trk): a 2020-2022 patent update. Expert opinion on therapeutic patents 34 (4) (2024)
Enrico Mario Alessandro Fassi, Andrea Citarella, Marco Albani, Erica Ginevra Milano, Laura Legnani, Carmen Lammi, Alessandra Silvani, Giovanni Grazioso
PCSK9 inhibitors: a patent review 2018-2023. Expert opinion on therapeutic patents 34 (4) (2024)

volume 34, number 5, 2024

Anushka Sharma, Rahul Dubey, Shankar Gupta, Vivek Asati, Vipul Kumar, Dileep Kumar, Debarshi Kar Mahapatra, Meenakshi Jaiswal, Sanmati Kumar Jain, Sanjay Kumar Bharti
PIM kinase inhibitors: an updated patent review (2016-present). Expert opinion on therapeutic patents 34 (5) (2024)
Alessia Petrocchi, Alina Ciammaichella
A patent review of SHP2 allosteric inhibitors (2018-present). Expert opinion on therapeutic patents 34 (5) (2024)
James S Scott, Teresa C M Klinowska
Selective estrogen receptor degraders (SERDs) and covalent antagonists (SERCAs): a patent review (July 2021-December 2023). Expert opinion on therapeutic patents 34 (5) (2024)
Rosa Maria Vitale, Luciano De Petrocellis, Pietro Amodeo
An updated patent review of TRPA1 antagonists (2020 - present). Expert opinion on therapeutic patents 34 (5) (2024)
Clemente Capasso, Claudiu T Supuran
Biomedical applications of prokaryotic carbonic anhydrases: an update. Expert opinion on therapeutic patents 34 (5) (2024)
Guo-Feng Xin, Nan-Nan Chen, Lin-Lin Li, Xue-Chun Liu, Chun-Chen Che, Bei-Duo Wu, Qi-Dong You, Xiao-Li Xu
An updated patent review of stimulator of interferon genes agonists (2021 - present). Expert opinion on therapeutic patents 34 (5) (2024)
Anushka Sharma, Rahul Dubey, Shankar Gupta, Vivek Asati, Vipul Kumar, Dileep Kumar, Debarshi Kar Mahapatra, Meenakshi Jaiswal, Sanmati Kumar Jain, Sanjay Kumar Bharti
PIM kinase inhibitors: an updated patent review (2016-present). Expert opinion on therapeutic patents 34 (5) (2024)
Alessia Petrocchi, Alina Ciammaichella
A patent review of SHP2 allosteric inhibitors (2018-present). Expert opinion on therapeutic patents 34 (5) (2024)
Clemente Capasso, Claudiu T Supuran
Biomedical applications of prokaryotic carbonic anhydrases: an update. Expert opinion on therapeutic patents 34 (5) (2024)
Rosa Maria Vitale, Luciano De Petrocellis, Pietro Amodeo
An updated patent review of TRPA1 antagonists (2020 - present). Expert opinion on therapeutic patents 34 (5) (2024)

volume 34, number 6, 2024

Alessandra Ammazzalorso, Arianna Granese, Barbara De Filippis
Recent trends and challenges to overcome Pseudomonas aeruginosa infections. Expert opinion on therapeutic patents 34 (6) (2024)
Bianca Laura Bernardoni, Ilaria D'Agostino, Concettina La Motta, Andrea Ageli
An insight into the last 5-year patents on Porphyromonas gingivalis and Streptococcus mutans , the pivotal pathogens in the oral cavity. Expert opinion on therapeutic patents 34 (6) (2024)
Valentina Puca, Beatrice Marinacci, Benedetta Pellegrini, Floriana Campanile, Maria Santagati, Rossella Grande
Biofilm and bacterial membrane vesicles: recent advances. Expert opinion on therapeutic patents 34 (6) (2024)
Clemente Capasso, Claudiu T Supuran
Carbonic anhydrase and bacterial metabolism: a chance for antibacterial drug discovery. Expert opinion on therapeutic patents 34 (6) (2024)
Francesco Melfi, Simone Carradori, Noemi Mencarelli, Cristina Campestre, Arianna Granese, Mattia Mori
Recent developments of agents targeting Vibrio cholerae : patents and literature data. Expert opinion on therapeutic patents 34 (6) (2024)
Sébastien Clément, Jean-Yves Winum
Photodynamic therapy alone or in combination to counteract bacterial infections. Expert opinion on therapeutic patents 34 (6) (2024)
Claudiu T Supuran
Fighting antibacterial drug resistance. Expert opinion on therapeutic patents 34 (6) (2024)
Luigi Pisano, Simone Giovannuzzi, Claudiu T Supuran
Management of Neisseria gonorrhoeae infection: from drug resistance to drug repurposing. Expert opinion on therapeutic patents 34 (6) (2024)

volume 34, number 7, 2024

Massimiliano Gasparrini, Simone Giovannuzzi, Alessio Nocentini, Nadia Raffaelli, Claudiu T Supuran
Inhibition of nicotinamide phosphoribosyltransferase (NAMPT) in cancer: a patent review. Expert opinion on therapeutic patents 34 (7) (2024)
Monica Viviano, Alessandra Cipriano, Emanuele Fabbrizi, Alessandra Feoli, Sabrina Castellano, Gianluca Sbardella, Antonello Mai, Ciro Milite, Dante Rotili
Successes and challenges in the development of BD1-selective BET inhibitors: a patent review. Expert opinion on therapeutic patents 34 (7) (2024)
Antimo Gioiello, Emiliano Rosatelli, Bruno Cerra
Patented Farnesoid X receptor modulators: a review (2019 - present). Expert opinion on therapeutic patents 34 (7) (2024)
Mourad A M Aboul-Soud, Yazeed A Al-Sheikh, Hazem K Ghneim, Claudiu T Supuran, Fabrizio Carta
Kinase inhibitors: 20 years of success and many new challenges and recent trends in their patents. Expert opinion on therapeutic patents 34 (7) (2024)
Massimiliano Gasparrini, Simone Giovannuzzi, Alessio Nocentini, Nadia Raffaelli, Claudiu T Supuran
Inhibition of nicotinamide phosphoribosyltransferase (NAMPT) in cancer: a patent review. Expert opinion on therapeutic patents 34 (7) (2024)
Giuseppina De Simone, Claudiu T Supuran
Anticancer drugs: where are we now? Expert opinion on therapeutic patents 34 (7) (2024)
Monica Viviano, Alessandra Cipriano, Emanuele Fabbrizi, Alessandra Feoli, Sabrina Castellano, Gianluca Sbardella, Antonello Mai, Ciro Milite, Dante Rotili
Successes and challenges in the development of BD1-selective BET inhibitors: a patent review. Expert opinion on therapeutic patents 34 (7) (2024)
Antimo Gioiello, Emiliano Rosatelli, Bruno Cerra
Patented Farnesoid X receptor modulators: a review (2019 - present). Expert opinion on therapeutic patents 34 (7) (2024)

volume 34, number 8, 2024

Wiktor Uzar, Beata Kaminska, Hubert Rybka, Łukasz Skalniak, Katarzyna Magiera-Mularz, Radoslaw Kitel
An updated patent review on PD-1/PD-L1 antagonists (2022-present). Expert opinion on therapeutic patents 34 (8) (2024)
Wiktor Uzar, Beata Kaminska, Hubert Rybka, Łukasz Skalniak, Katarzyna Magiera-Mularz, Radoslaw Kitel
An updated patent review on PD-1/PD-L1 antagonists (2022-present). Expert opinion on therapeutic patents 34 (8) (2024)
Ya-Xi Ye, Yu-Yao Cao, Li-Sheng Xu, Hai-Chao Wang, Xin-Hua Liu, Hai-Liang Zhu
FAK inhibitors in cancer, a patent review - an update on progress. Expert opinion on therapeutic patents 34 (8) (2024)
Miroslav Kosar, Leonard Mach, Erick M Carreira, Marc Nazaré, Pal Pacher, Uwe Grether
Patent review of cannabinoid receptor type 2 (CB 2 R) modulators (2016-present). Expert opinion on therapeutic patents 34 (8) (2024)
Kai Wang, Fen Zhong, Zhou-Dong Zhang, Huan-Qiu Li, Sheng Tian
Recent advances in the development of P2Y 14 R inhibitors: a patent and literature review (2018-present). Expert opinion on therapeutic patents 34 (8) (2024)
Hidayat Hussian, Daijie Wang, Hesham R El-Seedi, Luay Rashan, Ishtiaq Ahmed, Muzaffar Abbas, Nilufar Z Mamadalieva, Haider N Sultani, Muhammad Iftikhar Hussain, Syed Tasadaque A Shah
Therapeutic potential of boswellic acids: an update patent review (2016-2023). Expert opinion on therapeutic patents 34 (8) (2024)
Yuhang Li, Le Yang, Xiaoran Li, Xiaojin Zhang
Inhibition of GTPase KRAS G12D : a review of patent literature. Expert opinion on therapeutic patents 34 (8) (2024)
Ya-Xi Ye, Yu-Yao Cao, Li-Sheng Xu, Hai-Chao Wang, Xin-Hua Liu, Hai-Liang Zhu
FAK inhibitors in cancer, a patent review - an update on progress. Expert opinion on therapeutic patents 34 (8) (2024)
Jiaming Liu, Yinli Gao, Xiaojin Zhang
A patent review on hypoxia-inducible factor (HIF) modulators (2021-2023). Expert opinion on therapeutic patents 34 (8) (2024)
Miroslav Kosar, Leonard Mach, Erick M Carreira, Marc Nazaré, Pal Pacher, Uwe Grether
Patent review of cannabinoid receptor type 2 (CB 2 R) modulators (2016-present). Expert opinion on therapeutic patents 34 (8) (2024)
Kai Wang, Fen Zhong, Zhou-Dong Zhang, Huan-Qiu Li, Sheng Tian
Recent advances in the development of P2Y 14 R inhibitors: a patent and literature review (2018-present). Expert opinion on therapeutic patents 34 (8) (2024)
Yuhang Li, Le Yang, Xiaoran Li, Xiaojin Zhang
Inhibition of GTPase KRAS G12D : a review of patent literature. Expert opinion on therapeutic patents 34 (8) (2024)

volume 34, number 9, 2024

Chen Zhang, Zhao-Hang Xue, Wei-Hao Luo, Mei-Yan Jiang, Yinuo Wu
The therapeutic potential of phosphodiesterase 9 (PDE9) inhibitors: a patent review (2018-present). Expert opinion on therapeutic patents 34 (9) (2024)
Xiaoling Huang, Shidi Xu, Lei Duan, Shan Xu, Wufu Zhu
A patent review of small molecule CDK4/6 inhibitors in the treatment of cancer: 2020-present. Expert opinion on therapeutic patents 34 (9) (2024)
Rahul Baghel, Nikita Chhikara, Pawan Kumar, Akhilesh Kumar Tamrakar
SGLT2 inhibitors for the treatment of diabetes: a patent review (2019-23). Expert opinion on therapeutic patents 34 (9) (2024)
Margaux Morez, Antonio Jesús Lara Ordóñez, Patricia Melnyk, Maxime Liberelle, Nicolas Lebègue, Jean-Marc Taymans
Leucine-rich repeat kinase 2 (LRRK2) inhibitors for Parkinson's disease: a patent review of the literature to date. Expert opinion on therapeutic patents 34 (9) (2024)
Mohammad Mahboubi-Rabbani, Amir Hossein Abdolghaffari, Mahsa Ghesmati, Ali Amini, Afshin Zarghi
Selective COX-2 inhibitors as anticancer agents: a patent review (2018-2023). Expert opinion on therapeutic patents 34 (9) (2024)
Shirong Bian, Ru Zhang, Jianyu Nie, Mingxing Zhu, Zhouling Xie, Chenzhong Liao, Qin Wang
Progress with polo-like kinase (PLK) inhibitors: a patent review (2018-present). Expert opinion on therapeutic patents 34 (9) (2024)